<DOC>
	<DOC>NCT00889473</DOC>
	<brief_summary>This study will look at one dose of AT1001 for efficacy and safety for the treatment of celiac disease. The primary efficacy outcome is the rate of response to gluten.</brief_summary>
	<brief_title>Study of the Efficacy of AT1001 (Larazotide Acetate) to Treat Celiac Disease</brief_title>
	<detailed_description>This is an outpatient, randomized, double-blind multicenter study. Subjects will remain on their gluten-free diet throughout the duration of the trial. Study drug or drug placebo capsules will be administered TID 15 minutes before each meal (breakfast, lunch, and dinner). Gluten or gluten placebo capsules will be taken TID with each meal.</detailed_description>
	<mesh_term>Celiac Disease</mesh_term>
	<criteria>1. Age between 18 and 72 years, inclusive 2. Diagnosed with Celiac Disease for more than 12 months 3. Antitissue Transglutaminase (antitTG) less than 10 EU 4. On a glutenfree diet for at least 12 months 5. BMI between 18.5 and 38, inclusive 1. Current smoker 2. Has chronic active GI disease other than Celiac Disease (e.g., Crohn's, colitis) 3. Has diabetes (Type 1 or Type 2) 4. Participated in any clinical drug study within the past 30 days or has had previous exposure to AT1001 5. Presents with or has a history of dermatitis herpetiformis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Celiac Disease</keyword>
	<keyword>Gluten</keyword>
</DOC>